[PDF][PDF] Novel insights into the management of rheumatoid arthritis: one year in review 2024
E Molteni, A Adinolfi, V Bondi, P Delvino… - Clinical and …, 2024 - clinexprheumatol.org
New evidence from 2023 has slightly shifted some perspectives on rheumatoid arthritis (RA)
management. Glucocorticoids have reaffirmed their role as bridging therapy, while novel …
management. Glucocorticoids have reaffirmed their role as bridging therapy, while novel …
[HTML][HTML] Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65)
M Benucci, M Bardelli, M Cazzato, F Bartoli… - Journal of Personalized …, 2024 - mdpi.com
Background: According to recent data, the age of patients could represent an important risk
factor for MACE (major cardiovascular events), cancer, and VTE (venous thromboembolism) …
factor for MACE (major cardiovascular events), cancer, and VTE (venous thromboembolism) …
Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital
MAR Huaranga, LAC Pascual, DV Sanchez… - Cureus, 2024 - pmc.ncbi.nlm.nih.gov
Background: Several Janus kinase (JAK) inhibitors have been developed in recent years.
These agents are widely applicable in clinical practice as an alternative treatment for …
These agents are widely applicable in clinical practice as an alternative treatment for …
Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital
MA Ramírez Huaranga, LÁ Calvo Pascual… - 2024 - repositorio.comillas.edu
. Background: Several Janus kinase (JAK) inhibitors have been developed in recent years.
These agents are widely applicable in clinical practice as an alternative treatment for …
These agents are widely applicable in clinical practice as an alternative treatment for …